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1. Introduction 
1.1 High mortality in dialysis patients 
Dialysis patients have extraordinarily high mortality rates. Cardiac disease is the major 
cause of death accounting for 43% of all-cause mortality among patients receiving 
hemodialysis and peritoneal dialysis [Henry et al., 2002; US Renal Data System Annual Data 
Report Bethesta, 2005]. In previous report, patients with end-stage kidney disease (chronic 
kidney disease (CKD) stage 5) on dialysis, in comparison with the general population, also 
have a 3- to 30-fold increase in mortality, depending on the age group examined, and 
cardiovascular disease accounts for more than half of all deaths, with myocardial infarction, 
ischaemic cardiomyopathy, stroke and peripheral vascular disease making up the bulk of 
deaths (Foley et al., 1998). The marked excess in cardiovascular mortality in CKD, compared 
with the general population, is not explained by the presence of traditional Framingham risk 
factors, such as diabetes, smoking, hypertension and elevated cholesterol levels ( Zoccali, 
2000; Longenecker et al., 2002). With vascular calcification and arterial stiffness being 
observed in young and middle-aged dialysis patients without conventional cardiovascular 
risk factors (London et al., 2003), the search for non-traditional risk factors has led to 
increasing evidence of a multitude of factors that contribute to ectopic calcification in CKD.  
1.2 High mortality rate and hyperphosphatemia 
Inorganic phosphate (phosphate) retention, or hyperphosphatemia, has been identified as 
playing a major role in the progression of renal failure and in the generation of secondary 
hyperparathyroidism and uremic bone disease (Slatopolsky et al., 2002). Further 
observational data have also shown a significant association of hyperphosphatemia with 
increased mortality among patients who have end-stage kidney disease and are on 
hemodialysis (Block et al., 1998; Owen & Lowrie, 1998; Ganesh et al., 2001). Moreover, 
elevated serum phosphorus has been associated with an increased risk for cardiovascular 
mortality and hospitalization (all-cause, cardiovascular, and fracture) among dialysis 
patients (Block et al., 2004). Elevated phosphorus and Ca × P are also independent risk 
factors for all-cause and cardiovascular mortality in CKD stage 5, and increased levels of 
parathyroid hormone may be associated with both cardiovascular disease and increased 
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vascular calcification (Braun et al., 1996; Block et al., 1998; Ganesh et al., 2001; Wang et al., 
2003; Young et al., 2005). Thus, phosphorus has the potential to induce vascular calcification 
and may be cardiotoxic (Achinger & Ayus, 2006). Hyperphosphatemia is sometimes 
regarded as a distinct syndrome (Hruska et al., 2008), and its treatment should be 
considered preferentially and even independently of other laboratory values (Fig. 1).  
 
Hyperphosphatemia
Vascular calcification, Arterial stiffness, Endothelial dysfunction
Atherosclerosis, Arteriolosclerosis, Arterial thickening
Left ventricular hypertrophy, Cardiac interstitial fibrosis
Cardiovascular disease
myocardial infarction, ischemic infarction
stroke, peripheral vascular disease
High mortality  Sudden death
Hyperparathyroidism   1,25(OH)2D          FGF23    Klotho
 
Fig. 1. Hyperphosphatemia in hemodialysis 
2. Phosphate metabolism in human 
2.1 Phosphate metabolism in normal physiology 
Phosphorus is essential for multiple and diverse biological functions, including cellular 
signal transduction, mineral metabolism, and energy exchange. Although more than 80% of 
total body phosphorus is stored in bone and teeth, intracellular phosphorus exists in the 
form of organic compounds such as adenosine triphosphate and as free anions like H2PO4-, 
which are commonly referred to as phosphate. Serum phosphorus primarily occurs in the 
form of inorganic phosphate, which is maintained within the physiological range by 
regulation of dietary absorption, bone formation, and renal excretion, as well as 
equilibration with intracellular stores (Takeda et al., 2000; Bringhurst et al., 2004; Fukagawa 
et al., 2004; Blumsohn, 2004).  
Phosphate absorption in the renal proximal tubule and the small intestine is important for 
phosphate homeostasis. This is a major regulator of phosphate homeostasis and has the 
phosphate reabsorptive capacity to accommodate physiologic phosphate requirement. Up to 
70% of filtered phosphate is reabsorbed in the proximal tubule where sodium-dependent 
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phosphate transport systems in the brush-border membrane mediate the rate limiting step 
in the overall phosphate reabsorptive process (Murer et al, 2000; Takeda et al, 2000; 
Miyamoto et al, 2007; Tenenhouse, 2005; Biber et al, 2009). Three different types of sodium-
dependent phosphate transporters have been identified till now, types I, II and III. The 
sodium-dependent phosphate transport system includes the type IIa and type IIc Na-
dependent phosphate cotransporters, which are localized in the apical membrane of the 
renal proximal tubular cells, and the type IIb Na-dependent phosphate cotransporter, which 
is localized in the apical membrane of the intestinal epithelial cells. The type IIa Na-
dependent phosphate transporter is the major determinant of plasma phosphate level and 
urinary phosphate excretion (Murer et al, 2000; Takeda et al, 2000; Miyamoto et al, 2007; 
Tenenhouse, 2005; Biber et al, 2009). This transporter is regulated by physiological stimuli, 
for example, type IIa transporter levels in the apical membrane are increased in response to 
dietary restriction of phosphate and 1,25-dihydroxy-vitamin D3 [1,25(OH)2D3] and 
decreased in response to parathyroid hormone, or a high- phosphate diet. In addition, 
intestinal phosphate transport activity and type IIb Na-dependent phosphate transporter 
levels are upregulated by 1,25(OH)2D3 (Xu et al., 2002; Segawa et al., 2004).  
In addition, fibroblast growth factor 23 (FGF23), a recently identified member of the FGF 
family, is involved in renal phosphate homeostasis (Yu X & White, 2005; Yu & White, 2005). 
FGF23 induces urinary phosphate excretion by suppressing the expression of type IIa and 
IIc Na-dependent phosphate cotransporters in the brush border of renal proximal tubules 
(Shimada et al., 2004; Shimada et al., 2005). It also suppresses 1,25(OH)2D production by 
inhibiting 1a-hydroxylase (CYP27B1), which converts 25-hydroxyvitamin D [25(OH)D] to 
1,25(OH)2D, and by stimulating 24-hydroxylase (CYP24), which converts 1,25(OH)2D to 
inactive metabolites in the proximal tubule of the kidney (Shimada et al., 2004; Shimada et 
al., 2005). Given the fact that FGF23 promotes renal phosphaturia, its secretion should be 
regulated by serum phosphate levels. Experimental and clinical studies showed that several 
days of dietary phosphate loading lead to an increase in serum FGF23 in humans (Ferrari et 
al, 2005; Perwad et al., 2005; Nishida et al., 2006).  
2.2 Phosphate metabolism in hemodialysis patients 
Several studies have measured circulating FGF23 levels in predialysis and dialysis patients 
and reported progressively elevated FGF23 levels as serum creatinine or phosphate levels 
increase (Larsson et al., 2003; Imanishi et al., 2004). Thus, it appears that in patients with 
CKD, FGF23 production increases to counteract chronic phosphate retention by promoting 
urinary phosphate excretion in the face of reduced nephron mass. Notably, in this setting, a 
previous study showed that FGF23 was a strong independent predictor of diminished 
1,25(OH)2D levels, even after adjustment for renal function, serum phosphorus levels and 
25(OH)D levels (Gutierrez et al., 2005). This finding suggests that in patients with CKD, 
increases in FGF23 intended to maintain neutral phosphate balance result in suppression of 
renal 1,25(OH)2D production, thereby triggering the early development of secondary 
hyperparathyroidism (Fig. 1). 
3. Cardiovascular disease in hemodyalysis 
3.1 Hyperphosphatemia and cardiovascular disease 
Cardiomyopathy and ischemic heart disease including acute myocardial infarctions, which 
are both common conditions in dialysis patients, likely play a role in the development of 
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sudden death. After percutaneous and surgical coronary revascularization, dialysis patients 
are still remaining at a high risk for sudden cardiac death (Furgeson, 2008). 
Hyperphosphatemia is a known factor contributing to the increased risk of cardiac death 
both in patients with end-stage renal disease and in those under renal replacement 
treatment with dialysis (Goodman et al., 2000). In patients with renal disease, in fact, the 
well-known relationship between hyperphosphataemia, secondary hyperparathyroidism, 
bone turnover and extra osseous calcifications has recently been followed by the recognition 
of a major role played by elevated serum phosphorus levels in the induction of vascular 
calcification, cardiac interstitial fibrosis and arterial thickening which highly increase the 
risk of cardiac death (Goodman et al., 2000; Block & Port, 2000; Amann et al., 2003; 
Goldsmith et al., 2004; Floege & Ketteler, 2004).  
3.2 Vascular calcification 
Phosphate is probably the predominant inducer of vascular calcification, and elevated 
serum levels are strongly associated with increased vascular calcification and mortality 
(Goodman et al., 2000). Elevated phosphate triggers a concentration-dependent precipitation 
of calcium in vascular smooth muscle cells, and phosphate is also a potent stimulus for the 
differentiation of vascular smooth muscle cells. In vitro studies demonstrate that high 
phosphate levels in incubation media enhance calcification with associated extracellular 
matrix synthesis(Jono et al., 2000). Phosphate and sodium dependent phosphate transporter 
seem to play a very important role in vascular smooth muscle cells mineralization. Type III 
sodium-dependent phosphate transporter presents two discrete subtypes, Pit-1 and Pit-2. In 
human vascular smooth muscle cells, Pit-1 is mainly expressed (London et al., 2000). Apatite 
formation by smooth muscle cells, as a response to increased phosphate levels, is fully 
inhibited by phosphonoformic acid (PFA), a sodium dependent phosphate transporter 
inhibitor, a finding supporting the notion that vascular calcification is an active rather than 
passive cellular process (Giachelli et al., 2001; Ketteler et al., 2003). 
Hyperphosphataemia induces osteocalcin and Cbfa-1 in vascular smooth muscle cells and 
promotes vascular calcification. Animals deficient in Cbfa-1 fail to mineralize bone(Komori 
et al., 1997), and there is also increased expression of Cbfa-1 when vascular smooth muscle 
cells are incubated in uremic serum compared with pooled human serum (Moe et al., 2003). 
There is now considerable evidence that hyperphosphataemia regulates several signalling 
pathways of cell functions. Of great interest is the recent identification of a novel phosphate-
regulating gene, klotho (Kuro-o et al., 1997; Yoshida et al., 2002), which in mice is involved 
in the development of a syndrome resembling human ageing. The klotho mutant mice show 
abnormal calcium phosphate vitamin D metabolism and develop hyperphosphataemia and 
vascular calcification (Kuro-o et al., 1997; Yoshida et al., 2002). Hyperphosphataemia also 
down-regulates klotho gene expression (Fig. 1). 
3.3 Endothelial dysfunction 
Endothelial dysfunction is the principal cause of atherosclerosis resulting in cardio vascular 
disease (Ross, 1999). High phosphate loading on endothelial cells inhibited nitrogen oxide 
(NO) production through increased reactive oxygen species (ROS) production and 
endothelial NO syntase (eNOS) inactivation via conventional protein kinase C, resulting in 
impaired endothelium-dependent vasodilation (Shuto et al., 2009). Furthermore, dietary 
phosphate loading can deteriorate flow-mediated vasodilation in healthy men, suggesting 
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that dietary phosphate loading or elevation of serum phosphorus level may be a risk factor 
for cardiovascular disease in healthy persons as well as CKD patients (Takeda et al., 2006; 
Shuto et al., 2009). Di Marco et al. also reported that high phosphate loading increased ROS 
production via phosphate influx and induced apoptosis in endothelial cells (Di Marco et al., 
2008). Association of serum phosphorus level and vascular dysfunction has been well 
investigated, because fasting serum phosphorus level could not increase in healthy persons, 
even if dietary phosphate was overloaded. However, postprandial phosphorus elevation 
was associated with %FMD in young healthy men (Shuto et al., 2009). Thus, dietary 
phosphate loading can cause endothelial dysfunction within a short time. Oxidative stress 
and decreased NO production in endothelial cells are possible mechanisms for the impaired 
endothelial function mediated by phosphate loading (Fig. 2).  
 
PKC⇑
NAD(P)H Oxidase⇑ eNOS ⇓
ROS⇑ NO⇓
inflammatory cytokine ⇑
adhesion molecules ⇑
Endothelial dysfunction
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Induction of osteoblast differentiation
Smooth 
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Atherosclerosis
Mönkeberg’s
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Cardio
Vascular
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Endothelial
cell Vasorelaxation ⇓
 
Fig. 2. Dual pathways for vascular dysfunction caused by hyperphosphatemia 
3.4 Arterial stiffness 
Arterial disease observed in end-stage kidney disease patients is characterized by extensive 
intimal as well as medial calcification. Histological changes in coronary arteries from 
dialysis patients, compared with age matched controls, reveal a similar magnitude of 
atherosclerotic plaque burden and intimal thickness but markedly increased medial 
calcification (arteriolosclerosis) (Schwarz et al., 2000). Medial calcification has been shown to 
affect vascular elasticity and leads to increased arterial wall stiffness of large capacity, 
elastic-type arteries like the aorta and the common carotid artery, increased pulse pressure 
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and decreased perfusion of coronary arteries during diastole (Blacher et al., 1998; London, 
2003; Speer & Giachelli, 2004). Recent studies also demonstrated that elevated FGF23 levels 
were associated with arterial stiffness, increased left ventricular mass index and increased 
prevalence of left ventricular hypertrophy in patients with CKD (Hsu & Wu, 2009; Mirza et 
al., 2009; Gutierrez et al., 2009).  
4. Management of hyperphosphatemia in hemodialysis patients 
4.1 Target of management 
As elevated serum phosphorus and calcium levels are associated with vascular calcification 
and cardiovascular mortality in CKD, priority should be given to normalization of these 
parameters. It is generally accepted that adequate control of serum phosphorus remains a 
cornerstone in the clinical management of patients with CKD not only to attenuate the 
progression of secondary hyperparathyroidism but also possibly to reduce the risk for 
vascular calcification and cardiovascular mortality. A Ca x P more tan 72 mg2/dl2 is 
associated with a significant increase in the relative risk (RR) of mortality (RR = 1.34) 
compared with Ca x P less than 50 mg2/dl2 (Cozzolino et al., 2001). In a study in patients on 
hemodialysis, those who did not experience valvular calcification had maintained Ca x P at 
an average of 51 mg2/dl2 in the 6 months prior to the study, while those who did experience 
valvular calcification had an average Ca x P of 60 mg2/dl2 (Ribeiro et al., 1998). The target of 
treatment should be to maintain serum phosphorus level less than 5 mg/dl with serum 
calcium level less than 10 mg/dl to prevent cardio vascular consequences. This will allow 
the maintenance of Ca x P less than 50 mg2/dl2, a level which available evidence has so far 
shown not to promote calcification or increase mortality (Ribeiro et al., 1998).  
High FGF23 levels are more strongly associated with kidney disease progression, left 
ventricular hypertrophy, vascular disease, and mortality than serum phosphorus levels, and 
were most predictive of adverse events in patients with normal serum phosphorus 
(Thadhani et al., 2008; Oliveira et al., 2010). Dietary phosphate binders can lower FGF23 in 
CKD (Oliveira et al., 2010). Management of hyperphosphatemia relies on dietary restriction, 
the use of phosphate binders and dialysis.  
4.2 Dietary restriction of phosphate intake 
The average diet in North America and Europe contains approximately 1,000 to 1,500 mg of 
phosphorus per day (Willett & Buzzard, 1998). Dietary approach to phosphate retention in 
advanced renal failure patients, dietary approach to phosphate reduction is an important 
step in the treatment of hyperphosphatemia. The level of expression of klotho mRNA was 
greatly reduced in the kidneys of all chronic renal failure patients. Dietary phosphate 
restriction induced klotho expression, which enhances the beneficial effect of phosphate 
restriction in patients with chronic renal failure and or on hemodialysis. However, dietary 
restriction cannot considerably reduce the level of phosphate retention. As dialysis patients 
tend to need higher levels of protein due to the losses via dialysis, tight restriction on 
phosphate is difficult without compromising a patient's nutritional status. Because most 
dietary phosphate is contained in protein-rich foods, there is some concern about excessive 
protein restriction. In fact, the minimum amount of protein of 1.2 g/kg body weight/day, 
recommended to prevent malnutrition makes planning a diet with less than 1 g of 
phosphorus impossible (Kopple, 2001; Eknoyan et al., 2003). Recommendations that call for 
1.0 to 1.2 g/kg/day protein will usually obligate a phosphorus intake of 800 to 1,400 
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mg/day. Net phosphorus absorption averages 60% to 70% of intake (Delmez & Slatopolsky, 
1992; Sheikh et al., 1989), however, this percentage can rise as high as 86% of ingested 
phosphate with calcitriol use and decrease to 30% to 40% of ingested phosphate with 
optimal binder usage.(Sheikh et al., 1989; Delmez & Slatopolsky, 1992). 
Other foods that are high in phosphate are processed foods such as processed meats which 
have phosphate based additives to improve the consistency and appearance of the food. 
Since 1990, intake of phosphate from additives has doubled and has been 1,000 mg in USA 
(Calvo & Park, 1996). This is the amount that some renal patients are advised for the whole 
day from all food groups (James & Jackson, 2002). As people are becoming more reliant on 
processed and packaged meals due to convenience, phosphate from these sources needs to 
be considered when advising on diet. Fresh meat is considered suitable for someone 
following a phosphate restriction, however processed foods may in fact be providing much 
more phosphate than realised (Sullivan et al., 2007). Beverages such as sodas, juices and 
sport drinks also contain phosphate additives (Murphy-Gutekunst, 2007). It has been 
estimated that for a person on hemodialysis the average phosphate removal per day is 300 
mg (Vaithilingham et al., 2004). This leaves the patient with a positive balance for 
phosphate.  
4.3 Hemodialysis 
The clearance of phosphate varies among the different modalities of dialysis. Ideally, 
adequate dialysis in any form would remove adequate amounts of all uremic toxins, 
including phosphate. Unfortunately, conventional thrice-weekly hemodialysis (4 h duration) 
removes approximately 900 mg of phosphorus each treatment (an average of only 300 
mg/day) (Gotch et al., 2003). Increasing the dosage of dialysis, preferably to lengthy three 
times per week dialysis, hemodiafiltration, or, even better, daily/nightly dialysis may 
prevent phosphorus retention and even require no dietary phosphate restriction or the 
withdrawal of phosphate binders (Maduell et al., 2003; Benaroia et al., 2008). However, 
regular dialysis treatment is not able to remove all the phosphorus ingested with a diet 
containing protein of 1.0 - 1.2 g/kg/day (Mallick & Gokal, 1999).  
4.4 Phosphate binders 
Isakova et al analyzed a prospective cohort study of 10,044 incident hemodialysis patients at 
Fresenius Medical Care facilities in 2004 and 2005 comparing 1-year all-cause mortality 
among patients who were treated with phosphate binders (Isakova et al., 2009). In an 
intention-to-treat analysis, they compared patients who began treatment with any 
phosphate binder during the first 90 days after initiating hemodialysis, with those who 
remained untreated during that period. Treatment with phosphate binders was 
independently associated with decreased mortality compared with no treatment. In the 
unmatched cohort, the phosphate binder-treated group had a relative risk reduction of 42%, 
while in the intention-to-treat and as-treated analyses, the magnitude of the survival benefit 
ranged between 18% and 30% in multivariate models. The association between use of 
phosphorus binders and survival was observed within each quartile of baseline serum 
phosphorus except the lowest. Results from human data suggest that lowering of 
phosphorus levels by intake of phosphate binders will substantially reduce serum FGF-23 
levels (Koiwa et al., 2005; Pande et al., 2006). In this prospective observational study, 
treatment with phosphate binders was associated with a reduced 1-year mortality among 
incident hemodialysis patients (Isakova et al., 2009).  
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Sevelamer hydrochloride and lanthanum carbonate are a phosphate binders containing 
neither calcium nor aluminium, and are useful in those being administered concurrent 
vitamin D to reduce the potential for hypercalcemia. Attenuation in the progression of 
coronary artery calcification, after 6 and 12 months, was shown in hemodialysis patients 
treated with sevelamer, with reduced serum calcium, compared with patients on calcium 
carbonate (Chertow et al., 2002). A more recent randomized study of 114 incident 
hemodialysis patients demonstrated a survival advantage for patients on sevelamer 
compared with calcium carbonate after 18-month follow up (Block et al., 2007). A further 
beneficial effect of sevelamer has been proved on markers of coronary artery and aortic 
calcification compared with calcium based phosphate binders (Chertow et al., 2002). The 
attenuation of vascular and, in particular, coronary calcifications compared with calcium-
based phosphate binders in end-stage kidney disease patients under dialysis has been 
studied by electron beam computed tomography (Raggi, 2002; Raggi, 2004). High doses of 
sevelamer (3.2–8 g/day) are necessary to bring hyperphosphatemia back to target level, and 
the number of pills per day (about 8 x 800 mg tablets) may certainly be a conditioning factor 
for the patient’s compliance (Chertow et al., 2002).  
Patients with end-stage kidney disease treated with lanthanum carbonate up to 2.5–3.8 
g/day for up to 2 years have been reported to obtain effective reduction of serum 
phosphorus level (Finn, 2006). Lanthanum-carbonate-treated patients have, also been shown 
to reach a significantly reduced calcium/phosphate product and parathyroid hormone level 
compared with the placebo (Joy & Finn, 2009). Lanthanum carbonate, therefore, is an 
effective, at least as effective as calcium carbonate, well-tolerated phosphate binder 
(Hutchison, 2004; Hutchison et al., 2006). However, despite the very encouraging results, 
further studies involving larger numbers of patients are needed to definitively establish the 
long-term safety of lanthanum regarding tissue deposition, as well as its efficacy on vascular 
calcifications or outcomes in treated patients, which also need to be confirmed in the long 
term. 
4.5 Combination in treatment 
A multiple-factor approach can be used to reduce serum phosphate including reduced 
phosphorus intake in the diet, using phosphate binders efficiently and avoidance of 
under- dialysis. The patient's diet should be high in nutrition but with the lowest possible 
phosphorus content. Since dietary control of phosphorus intake and dialysis removal are 
usually not sufficient, phosphate binders are usually needed as adjuvants to increase fecal 
excretion (Bover et al; 2005). For an optimal protein diet of 1-1.2 g/kg/day, the 
phosphorus intake was 778-1,444 mg/day and 5,500-10,000 mg/week. Dialysis has limited 
ability for phosphate control, although phosphate removal by hemodialysis is very much 
a time-dependent process. The amount of phosphorus removed by hemodialysis, 
extrapolated to an average week, is 250-300 mg/day. The introduction of non-calcium-
based phosphate binders has enabled a reduction in the total phosphate load and 
provides a useful tool in the prevention of vascular calcification in CKD. The use of 
phosphate binders may decrease the phosphorus absorbed from the diet to 40% (Llach & 
Bover, 2000). In these circumstances, 320 mg of phosphorus and 21g of protein (0.3-0.35g 
of protein/kg/day) intake should be the critical value above which a positive balance of 
phosphate may occur (Fig. 3).  
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Dietary intake
Protein     non-restricted   restricted
(mg/kg/day)      1.0-1.2          0.3-0.35
Phosphorus 
(mg/week)   5,600-10,000      2,250
(mg/day)        800-1,400          320
Phosphate pool
(blood)
Hemodialysis
(900 mg/week)
Bone and soft tissue
Absorption
(2,000-4,000 mg/week)
(900 mg/week)
Phosphate
-binder
Stool
(3,000-6,000 mg/week)
(1,350 mg/week)
Intestine
 
Fig. 3. Phosphate balance in hemodialysis patient 
Those in restricted protein and phosphate intake are shown in bold. 
Successful control of phosphate is one of the key aspects in the management of dialysis 
patients (Rodriguez-Benot et al., 2005; Young et al., 2004, Young et al., 2005), However, 
numerous studies have revealed the difficulty in achieving phosphorus targets less than 5.5 
mg/dl (Arenas et al., 2006; Lorenzo et al., 2006: Wei et al., 2006), despite the wide variety of 
drugs available for its treatment (Joy & Finn, 2003; Sprague, 2007; Arenas et al., 2008). Both 
endothelial dysfunction and medial calcification are closely associated with development of 
cardiovascular disease. It is well known that long-term exposure to phosphate, generally 
observed in end-stage renal failure patients, can mediate vascular calcification (Jono et al., 
2000; Giachelli, 2003). Dietary high phosphate loading can be involved in the postprandial 
elevation of serum phosphorus level, and this short-term exposure to phosphate was 
enough to decrease endothelium-dependent vasodilation.  
5. Conclusion 
The goals of therapy have been to reduce phosphorus intake with low protein diet and 
phosphate binders. Since low protein diet is thought to be induce malnutrition, it is thought 
that strict adherence to a low protein diet is not practical. A diet rich in proteins is usually 
also rich in phosphorus. However, proteins with very different phosphorus contents can 
provide equivalent nutritional value, as can be seen from the difference in phosphorus 
content between meat, cheese, and eggs. Egg white is an excellent example of food with a 
high level of protein but low phosphorus content. Moe et al. demonstrates the importance of 
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the protein source of phosphate in overall mineral metabolism after only 7 days of 
controlled diets. Despite equivalent protein and phosphorus concentrations in the diets, 
subjects had lower serum phosphorus levels, a trend toward decreased urine 24-hour 
phosphorus excretion, and significantly decreased FGF23 levels in the vegetarian diet 
compared with the meat-based diet (Moe et al., 2011).  
Lafage et al. (Lafage et al., 1992) used a very low protein diet (0.3 g/kg/d) supplemented 
with amino acids and ketoanalogues and with only 1 g of calcium carbonate and 1,000 IU of 
vitamin D2 in 17 patients with advanced renal failure. They have shown not only a beneficial 
effect related to the control of hyperphosphatemia on the biologic and histologic parameters 
of hyperparathyroidism but also a correction of acidosis, which resulted in the 
disappearance of the osteomalacic component. Thus, dietary control often considered to be 
of minor importance, is actually one of the major keys to success in the management of 
hyperphosphataemia. 
6. Acknowledgements 
The work described in this publication was supported by Grants-in-Aid for Scientific 
Research from the Ministry of Education, Culture, Sports, Science and Technology in Japan 
(to ET, HY, and YT). 
7. References 
Achinger SG, Ayus JC. (2006) Left ventricular hypertrophy: is hyperphosphatemia among 
dialysis patients a risk factor? J Am Soc Nephrol 17(12 suppl 3): S255-S261. 
Amann K, Törnig J, Kugel B, Gross ML, Tyralla K, El-Shakmak A, Szabo A, Ritz E. (2003) 
Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in 
experimental uremia. Kidney Int 63: 1296–1301. 
Arenas MD, Alvarez-Ude F, Gil MT, Soriano A, Egea JJ, Millán I, Amoedo ML, Muray S, 
Carretón MA. (2006) Application of NKFK/DOQI clinical practice guidelines for 
bone metabolism and disease: changes of clinical practices and their effects on 
outcomes and quality standards in three haemodialysis units. Nephrol Dial 
Transplant. 21: 1663-1668. 
Arenas MD, Malek T, Gil MT, Moledous A, Nunez C, Alvarez-Ude F. (2008) Use of 
aluminum-based phosphate-chelators in hemodialysis in the era of ultrapure water. 
Nefrologia. 28: 168-173. 
Benaroia M, Pierratos A, Nesrallah GE. (2008) A primer for the prescription of short-daily 
and nocturnal hemodialysis. Hemodial Int 12: 23-29. 
Biber J, Hernando N, Forster I, Murer H. (2009) Regulation of phosphate transport in 
proximal tubules. Pflu¨gers Arch 458: 39–52. 
Blacher J, Demuth K, Guerin AP, Safar ME, Moatti N, London GM, (1998) Influence of 
biochemical alterations on arterial stiffness in patients with end-stage renal disease. 
Arterioscler Thromb Vasc Biol 18: 535-541. 
Block GA, Hulbert-Shearon TE, Levin NW, Port FK. (1998) Association of serum phosphorus 
and calcium x phosphate product with mortality risk in chronic hemodialysis 
patients: A national study. Am J Kidney Dis 31: 607–617. 
www.intechopen.com
 
Complications and Managements of Hyperphosphatemia in Dialysis 
 
325 
Block GA, Port FK. (2000) Re-evaluation of risks associated with hyperphosphatemia and 
hyperparathyroidism in dialysis patients: recommendations for a change in 
management. Am J Kidney Dis 35: 1226–1237. 
Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. (2004) Mineral 
metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc 
Nephrol 15: 2208–2218. 
Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. (2007) Mortality effect of coronary 
calcification and phosphate binder choice in incident hemodialysis patients. Kidney 
Int. 71: 438–441. 
Blumsohn A. (2004) What have we learnt about the regulation of phosphate metabolism? 
Curr Opin Nephrol Hypertens. 13: 397– 401. 
Bover J, Ortiz-Herbener F, Ballarín J, Andrés E, Barceló P. (2005) New therapy strategies in 
secondary hyperparathyroidism on dialysis (I): new concepts, new treatments. 
Nefrologia. 25 Suppl 2: 100-108. 
Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC. (1996) Electron beam 
computed tomography in the evaluation of cardiac calcification in chronic dialysis 
patients. Am. J. Kidney Dis. 27: 394–401. 
Bringhurst FR, Demay BM, Krane SM, Kronenberg HM. (2004) Bone and mineral 
metabolism in health and disease. In: Kasper DL, Braunwald E, Fauci AS, Hauser 
SL, Longo DL, Jameson L, Isselbacher KJ, eds. Harrison’s Principles of Internal 
Medicine. New York, NY: McGraw-Hill. 
Calvo & Park 1996. Calvo MS, Park YK. (1996).Changing phosphorus content of the U.S. 
diet: potential for adverse effects on bone. J Nutr. 126(4 Suppl):1168S-1180S. 
Chertow GM, Burke SK, Raggi P. (2002) Sevelamer attenuates the progression of coronary 
and aortic calcification in hemodialysis patients. Kidney Int. 62: 245–52. 
Cozzolino M, Dusso AS, Slatopolsky D. (2001) Role of calciumphosphate product and bone-
associated proteins on vascular calcification in renal failure. J Am Soc Nephrol 12: 
2511–2516. 
Delmez JA, Slatopolsky E. (1992) Hyperphosphatemia: its consequences and treatment in 
patients with chronic renal disease. Am J Kidney Dis. 19(4):303-317. 
Di Marco GS, Hausberg M, Hillebrand U, Rustemeyer P, Wittkowski W, Lang D, 
Pavensta¨dt H. (2008) Increased inorganic phosphate induces human endothelial 
cell apoptosis in vitro. Am J Physiol Renal Physiol 294: F1381–1387. 
Eknoyan G, Levin A, Levin NW. National Kidney Foundation. (2003) Bone metabolism and 
disease in chronic kidney disease. Am J Kidney Dis 42 [Suppl 3]: S1–S201 
Ferrari SL, Bonjour JP, Rizzoli R. (2005) Fibroblast growth factor-23 relationship to dietary 
phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol 
Metab. 90: 1519-1524. 
Finn WF. SPD 405–307 Lanthanum Study Group. (2006) Lanthanum carbonate versus 
standard therapy for the treatment of hyperphosphatemia: safety and efficacy in 
chronic maintenance hemodialysis patients. Clin Nephrol 65(3): 191-202. 
Floege J, Ketteler M. (2004) Vascular calcification in patients with endstage renal disease. 
Nephrol Dial Transplant. 19 [Suppl 5]: V59–V66. 
Foley RN, Parfrey PS, Sarnak MJ. (1998) Clinical epidemiology of cardiovascular disease in 
chronic renal disease. Am. J. Kidney Dis. 32: S112–19. 
www.intechopen.com
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
326 
Fukagawa M, Kurokawa K, Papadakis MA. (2004) Fluid and electrolyte disorders. In: 
Tierney LM, McPhee SJ, Papadakis MA, eds. Current Medical Diagnosis and 
Treatment 2005. New York, NY: McGraw-Hill/Appleton & Lange; 837–867. 
Furgeson SB. (2008) Chonchol: Beta-blockade in chronic dialysis patients. Semin Dial 21: 43–
48. 
Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. (2001) Association of elevated 
serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality 
risk in chronic hemodialysis patients. J Am Soc Nephrol 12: 2131–2138. 
Giachelli SM, Jono S, Mori K, Morii H, (2001) Vascular calcification and inorganic 
phosphate. Am J Kidney Dis 38: S34-37. 
Giachelli CM. (2003) Vascular calcification: In vitro evidence for the role of inorganic 
phosphate. J Am Soc Nephrol 14: S300–S304. 
Goldsmith D, Ritz E, Covic A. (2004) Vascular calcification: a stiff challenge for the 
nephrologist. Kidney Int 66: 1315–1333 
Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick 
A, Greaser L, Elashoff RM, Salusky IB. (2000) Coronary-artery calcification in 
young adults with end-stage renal disease who are undergoing dialysis. N Engl J 
Med 342: 1478–1483 
Gotch FA, Panlilio F, Sergeyeva O, Rosales L, Folden T, Kaysen G, Levin NW. (2003) A 
kinetic model of inorganic phosphorus mass balance in hemodialysis therapy. Blood 
Purif 21: 51–57. 
Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H, Wolf M. (2005) 
Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol 
deficiency in chronic kidney disease. J Am Soc Nephrol. 16: 2205-2215. 
Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, 
Thadhani R, Jüppner H, Wolf M. (2008) Fibroblast growth factor 23 and mortality 
among patients undergoing hemodialysis. N Engl J Med. 359(6): 584-592. 
Gutiérrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, 
Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M. (2009) 
Fibroblast growth factor-23 and left ventricular hypertrophy in chronic kidney 
disease. Circulation. 119: 2545-2552. 
Henry RM, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD: 
(2002) Mild renal insufficiency is associated with increased cardiovascular 
mortality: the Hoorn Study. Kidney Int  62: 1402–1407. 
Hruska KA, Mathew S, Lund R, Qiu P, Pratt R. (2008) Hyperphosphatemia of chronic 
kidney disease. Kidney Int 74: 148-157. 
Hsu HJ, Wu MS. (2009) Fibroblast growth factor 23: a possible cause of left ventricular 
hypertrophy in hemodialysis patients. Am J Med Sci. 337:116-122. 
Hutchison AJ. (2004) Improving phosphate-binder therapy as a way forward. Nephrol Dial 
Transplant 19 [Suppl 1]: i19–i24. 
Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, Schmieder R, Backs W, 
Jamar R, Vosskühler A. (2006) Long-term efficacy and tolerability of lanthanum 
carbonate: results from a 3-year study. Nephron Clin Pract 102: c61–c71. 
Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, Miura M, Miyauchi 
A, Kobayashi K, Miki T, Shoji T, Ishimura E, Nishizawa Y. (2004) FGF-23 in patients 
with end-stage renal disease on hemodialysis. Kidney Int. 65: 1943-1946. 
www.intechopen.com
 
Complications and Managements of Hyperphosphatemia in Dialysis 
 
327 
Isakova T, Gutiérrez OM, Chang Y, Shah A, Tamez H, Smith K, Thadhani R, Wolf M. (2009) 
Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol. 20: 388-396. 
James G, Jackson H: European guidelines for the nutritional care of adult renal patients. 
(2002) EDTNA/ERCA, pp1-52. 
Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM. (2000) 
Phosphate regulation of vascular smooth muscle cell calcification. Circ. Res. 87: 
E10–17. 
Joy MS, Finn WF. (2003) Randomized, double-blind, placebocontrolled, dose-titration, Phase 
III study assessing the efficacy and tolerability of lanthanum carbonate: a new 
phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 42: 96–
107. 
Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Böhm R, Metzger T, 
Wanner C, Jahnen-Dechent W, Floege J. (2003) Association of low fetuin-A (AHSG) 
concentrations in serum with cardiovascular mortality in patients on dialysis: a 
cross-sectional study. Lancet 361: 827–833. 
Koiwa F, Kazama JJ, Tokumoto A, Onoda N, Kato H, Okada T, Nii-Kono T, Fukagawa M, 
Shigematsu T; ROD21 Clinical Research Group. (2005) Sevelamer hydrochloride 
and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis 
patients. Ther Apher Dial 9: 336–339. 
Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, 
Gao YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T. (1997) 
Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to 
maturational arrest of osteoblasts. Cell. 89(5):755-764. 
Kopple JD. (2001) National Kidney Foundation K/DOQI clinical practice guidelines for 
nutrition in chronic renal failure. Am J Kidney Dis 37 [Suppl 2]: S66–S70. 
Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, 
Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa 
S, Nagai R, Nabeshima YI. (1997) Mutation of the mouse klotho gene leads to a 
syndrome resembling ageing. Nature 390: 45–51. 
Lafage MH, Combe C, Fournier A, Aparicio M. (1992) Ketodiet, physiological calcium intake 
and native vitamin D improve renal osteodystrophy. Kidney Int. 42(5): 1217-1225. 
Larsson T, Nisbeth U, Ljunggren O, Jüppner H, Jonsson KB. (2003) Circulating concentration 
of FGF-23 increases as renal function declines in patients with chronic kidney 
disease, but does not change in response to variation in phosphate intake in healthy 
volunteers. Kidney Int. 64: 2272-2279. 
Llach L, Bover J. (2000) Renal osteodystriphies; in Brenner BM (ed): The Kidney. Philadelphia, 
Saunders, pp2103-2186. 
London GM. (2000) Alterations of arterial function in end-stage renal disease. Nephron 84: 
111-118. 
London GM. (2003) Cardiovascular Calcifications in Uremic Patients: Clinical Impact on 
Cardiovascular Function. J Am Soc Nephrol 14: S305–S309. 
London GM, Guérin AP, Marchais SJ, Métivier F, Pannier B, Adda H. (2003) Arterial media 
calcification in end-stage renal disease: Impact on all-cause and cardiovascular 
mortality. Nephrol. Dial. Transplant 18: 1731–1740. 
www.intechopen.com
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
328 
Longenecker JC, Coresh J, Powe NR Levey AS, Fink NE, Martin A, Klag MJ. (2002) 
Traditional cardiovascular disease risk factors in dialysis patients compared with 
the general population: The CHOICE Study. J. Am. Soc. Nephrol. 13: 1918–1927. 
Lorenzo V, Martin-Malo A, Perez-Garcia R, Torregrosa JV, Vega N, de Francisco AL, Cases 
A. (2006) Prevalence, clinical correlates and therapy cost of mineral abnormalities 
among haemodialysis patients: a cross-sectional multicentre study. Nephrol Dial 
Transplant. 21: 459-465. 
Maduell F, Navarro V, Torregrosa E, Rius A, Dicenta F, Cruz MC, Ferrero JA. (2003) Change 
from three times a week on-line hemodiafiltration to short daily on-line 
hemodiafiltration. Kidney Int 64: 305-313. 
Mallick NP, Gokal R. (1999) Haemodialysis. Lancet 353: 737–742 
Mirza MA, Larsson A, Lind L, Larsson TE. (2009) Circulating fibroblast growth factor-23 is 
associated with vascular dysfunction in the community. Atherosclerosis. 205: 385-
390. 
Miyamoto K, Ito M, Tatsumi S, Kuwahata M, Segawa H. (2007) New aspect of renal 
phosphate reabsorption: the type IIc sodium-dependent phosphate transporter. Am 
J Nephrol 27: 503–515. 
Miyamoto K, Segawa H, Ito M, Kuwahata M. (2004) Physiological regulation of renal 
sodium-dependent phosphate cotransporters. Jpn J Physiol 54: 93–102. 
Moe SM, Duan D, Doehle BP, O'Neill KD, Chen NX. (2003) Uremia induces the osteoblast 
differentiation factor Cbfa1 in human blood vessels. Kidney Int. 63: 1003–1011. 
Moe SM, Zidehsarai MP, Chambers MA, Jackman LA, Radcliffe JS, Trevino LL, Donahue SE, 
Asplin JR. (2010) Vegetarian compared with meat dietary protein source and 
phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol. 6(2): 257-
264.  
Murer H, Hernando N, Forster I, Biber J. (2000) Proximal tubular phosphate reabsorption: 
molecular mechanisms. Physiol Rev 80: 1373–1409. 
Murphy-Gutekunst L. (2007) Hidden phosphorus: where do we go from here ? J Ren Nutr 4: 
e31-e36. 
Nishida Y, Taketani Y, Yamanaka-Okumura H, Imamura F, Taniguchi A, Sato T, Shuto E, 
Nashiki K, Arai H, Yamamoto H, Takeda E. (2006) Acute effect of oral phosphate 
loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int. 70: 
2141-2147. 
Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, 
Jorgetti V, Canziani ME, Moysés RM.. (2010) Early control of PTH and FGF23 in 
normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am 
Soc Nephrol. 5(2): 286-291.  
Owen WF, Lowrie EG: (1998) C-reactive protein as an outcome predictor for maintenance 
hemodialysis patients. Kidney Int 54: 607–617. 
Pande S, Ritter CS, Rothstein M, Wiesen K, Vassiliadis J, Kumar R, Schiavi SC, Slatapolsky 
E, Brown AJ. (2006) FGF-23 and sFRP-4 in chronic kidney disease and post-renal 
transplantation. Nephron Physiol 104: 23–32. 
Perwad F, Azam N, Zhang MY, Yamashita T, Tenenhouse HS, Portale AA. (2005) Dietary 
and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-
dihydroxyvitamin D metabolism in mice. Endocrinology. 146: 5358-5364. 
www.intechopen.com
 
Complications and Managements of Hyperphosphatemia in Dialysis 
 
329 
Raggi P. (2000) Detection and quantification of cardiovascular calcifications with electron 
beam tomography to estimate risk in hemodialysis patients. Clin Nephrol 54: 325–
333. 
Raggi P. (2002) Effects of excess calcium load on the cardiovascular system measured with 
electron beam tomography in end-stage renal disease. Nephrol Dial Transplant 17: 
332–335. 
Ribeiro S, Ramos A, Brandão A, Rebelo JR, Guerra A, Resina C, Vila-Lobos A, Carvalho F, 
Remédio F, Ribeiro F. (1998) Cardiac valve calcification in haemodialysis patients: 
role of calcium-phosphate metabolism. Nephrol Dial Transplant 13: 2037–2040. 
Rodriguez-Benot A, Martin-Malo A, Alvarez-Lara MA, Rodriguez M, Aljama P. (2005) Mild 
hyperphosphatemia and mortality in hemodialysis patients. Am J Kidney Dis. 46: 68-
77. 
Ross R. (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115–126. 
Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, Amann K. (2000) 
Morphology of coronary atherosclerotic lesions in patients with end-stage renal 
failure. Nephrol. Dial. Transplant. 15: 218–223. 
Segawa H, Kaneko I, Setsuko Y, Ito M, Kuwahata M, Inoue Y, Kato S, Miyamoto K. (2004) 
Intestinal Na-Pi cotransporter adaptation to dietary Pi content in vitamin D 
receptor null mice. Am J Physiol Renal Physiol 287: F39–F47. 
Seiler S, Reichart B, Roth D, Seibert E, Fliser D, Heine GH. (2010) FGF-23 and future 
cardiovascular events in patients with chronic kidney disease before initiation of 
dialysis treatment. Nephrol Dial Transplant. 25(12): 3983-3989. 
Sheikh MS, Maguire JA, Emmett M, Santa Ana CA, Nicar MJ, Schiller LR, Fordtran JS. (1989) 
Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, 
in vitro, and in vivo study. J Clin Invest. 83(1): 66-73. 
Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, 
Fukumoto S, Yamashita T. (2004) FGF-23 is a potent regulator of vitamin D 
metabolism and phosphate homeostasis. J Bone Miner Res. 19: 429-435. 
Shimada T, Yamazaki Y, Takahashi M, Hasegawa H, Urakawa I, Oshima T, Ono K, Kakitani 
M, Tomizuka K, Fujita T, Fukumoto S, Yamashita T. (2005) Vitamin D receptor-
independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am 
J Physiol Renal Physiol. 289: F1088-F1095. 
Shuto E, Taketani Y, Tanaka R, Harada N, Isshiki M, Sato M, Nashiki K, Amo K, Yamamoto 
H, Higashi Y, Nakaya Y, Takeda E. (2009) Dietary phosphorus acutely impairs 
endothelial function. J Am Soc Nephrol. 20(7): 1504-1512. 
Slatopolsky E, Brown A, Dusso A. (2002) Role of phosphorus in the pathogenesis of 
secondary hyperparathyroidism. Am J Kidney Dis 37: S54–S57. 
Speer MY, Giachelli CM, (2004) Regulation of cardiovascular calcification. Cardiovascular 
Pathology 13: 63-70. 
Sprague SM. (2007) A comparative review of the efficacy and safety of established 
phosphate binders: calcium, sevelamer, and lanthanum carbonate. Curr Med Res 
Opin. 23: 3167-3175. 
Sullivan CM, Leon JB, Sehgal AR. (2007) Phosphorus-containing food additives and the 
accuracy of nutrient databases: implications for renal patients. J Ren Nutr. 17(5): 
350-354. 
www.intechopen.com
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
330 
Takeda E, Taketani Y, Morita K, Tatsumi S, Katai K, Nii T, Yamamoto H, Miyamoto K. 
(2000) Molecular mechanisms of mammalian inorganic phosphate homeostasis. 
Adv Enzyme Regul 40: 285-302. 
Takeda E, Taketani Y, Nashiki K, Nomoto M, Shuto E, Sawada N, Yamamoto H, Isshiki M. 
(2006) A novel function of phosphate-mediated intracellular signal transduction 
pathways. Adv Enzyme Regul 46: 154–161. 
Tenenhouse HS. (2006) Regulation of phosphorus homeostasis by the type IIa 
Na/phosphate cotransporter. Annu Rev Nutr 25: 197–214. 
US Renal Data System Annual Data Report Bethesta (2005) National Institutes of Health 
National Institute of Diabetes and Digestive and Kidney Diseases. 
Vaithilingam I, Polkinghorne KR, Atkins RC, Kerr PG. (2004) Time and exercise improve 
phosphate removal in hemodialysis patients. Am J Kidney Dis. 43(1): 85-89. 
Wang AY, Wang M, Woo J, Lam CW, Li PK, Lui SF, Sanderson JE. (2003) Cardiac valve 
calcification as an important predictor for all-cause mortality and cardiovascular 
mortality in long-term peritoneal dialysis patients: A prospective study. J. Am. Soc. 
Nephrol. 14: 159–168. 
Wei M, Taskapan H, Esbaei K, Jassal SV, Bargman JM, Oreopoulos DG. (2006) K/DOQI 
guideline requirements for calcium, phosphate, calcium phosphate product, and 
parathyroid hormone control in dialysis patients: can we achieve them? Int Urol 
Nephrol. 38: 739-743. 
Willett WC, Buzzard M. (1998) Nature of Variation in Diet in Nutritional Epidemiology, 2nd Ed., 
edited by Willett WC, New York, Oxford University Press, pp33-49. 
Xu H, Bai L, Collins JF, Ghishan FK. (2002) Age-dependent regulation of rat intestinal type 
IIb sodium-phosphate cotransporter by 1,25-(OH2) vitamin D3. Am J Physiol Cell 
Physiol 282: C487–C493. 
Yoshida T, Fujimori T, Nabeshima Y. (2002) Mediation of unusually high concentrations of 
1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased 
expression of renal 1 alpha-hydroxylase gene. Endocrinology 143: 683–689. 
Young EW, Akiba T, Albert JM, McCarthy JT, Kerr PG, Mendelssohn DC, Jadoul M. (2004) 
Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in 
the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 
44(Suppl 2): 34-38. 
Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, 
Kurokawa K, Bommer J, Piera L, Port FK. (2005) Predictors and consequences of 
altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. 
Kidney Int. 67: 1179–1187. 
Yu X, White KE. (2005) Fibroblast growth factor 23 and its receptors. Ther Apher Dial 9: 308–
312. 
Yu X, White KE. (2005) FGF23 and disorders of phosphate homeostasis. Cytokine Growth 
Factor Rev 16: 221–232. 
Zoccali C. (2000) Cardiovascular risk in uraemic patients – Is it fully explained by classical 
risk factors? Nephrol. Dial. Transplant. 15: 454–457. 
 
www.intechopen.com
Progress in Hemodialysis - From Emergent Biotechnology to
Clinical Practice
Edited by Prof. Angelo Carpi
ISBN 978-953-307-377-4
Hard cover, 444 pages
Publisher InTech
Published online 07, November, 2011
Published in print edition November, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Hemodialysis (HD) represents the first successful long-term substitutive therapy with an artificial organ for
severe failure of a vital organ. Because HD was started many decades ago, a book on HD may not appear to
be up-to-date. Indeed, HD covers many basic and clinical aspects and this book reflects the rapid expansion of
new and controversial aspects either in the biotechnological or in the clinical field. This book revises new
technologies and therapeutic options to improve dialysis treatment of uremic patients. This book consists of
three parts: modeling, methods and technique, prognosis and complications.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Eiji Takeda, Hironori Yamamoto, Hisami Yamanaka-Okumura and Yutaka Taketani (2011). Complications and
Managements of Hyperphosphatemia in Dialysis, Progress in Hemodialysis - From Emergent Biotechnology to
Clinical Practice, Prof. Angelo Carpi (Ed.), ISBN: 978-953-307-377-4, InTech, Available from:
http://www.intechopen.com/books/progress-in-hemodialysis-from-emergent-biotechnology-to-clinical-
practice/complications-and-managements-of-hyperphosphatemia-in-dialysis
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
